Clinical Trials
42 trialsSafety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
Shanghai Pulmonary Hospital, Shanghai, China
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
Changhai Hospital
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Peking University
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PTCA199-16
Fudan University
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
Fudan University
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
LEFT-PANC
Helsinki University Central Hospital
YOUNG-NEOS
Peking University People's Hospital
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
Zhejiang Provincial People's Hospital
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Beijing Tongren Hospital
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SHIFT-001
Fudan University
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC
Beijing Tongren Hospital
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
OSCC
Shanghai Zhongshan Hospital
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
RenJi Hospital
Example
Hunan Province Tumor Hospital
Irinotecan Liposomeļ¼Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer
Harbin Medical University
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Xijing Hospital
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Liaoning Cancer Hospital & Institute
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Shanghai Chest Hospital
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University